File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL)

TitleAll-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL)
Authors
Keywordsacute promyelocytic leukemia
all-trans retinoic acid
event-free survival
Issue Date1996
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182
Citation
Hematological Oncology, 1996, v. 14 n. 3, p. 147-154 How to Cite?
AbstractAcute promyelocytic leukemia is characterized by the reciprocal translocation of chromosomes 15 and 17. All-trans retinoic acid (ATRA) efficiently induces differentiation of the abnormal promyelocytes. In this study, we had used ATRA as the primary induction therapy for 17 newly diagnosed patients, and as the salvage therapy for 11 patients who relapsed from or were resistant to chemotherapy. All patients received subsequent consolidation chemotherapy. Complete remission (CR) rate, early death rate (within 28 days of diagnosis) were then compared to an historical control of 50 APL patients treated with combination chemotherapy; and event-free survival of the 17 newly diagnosed patients was compared to the historical control. In the ATRA group, 26 of the 28 patients (93 per cent) attained complete remission. Two of 28 (7 per cent) died within 28 days of ATRA therapy. There was no case of primary resistance to ATRA. Combination chemotherapy was added to ATRA in five patients due to rapidly increasing leucocyte count. There was one case of retinoic acid syndrome which resolved with steroid. When compared to the 50 cases of historical control, there is significant improvement in the overall CR rate (92 per cent versus 59 per cent, p = 0.001) and a significant reduction in the early mortality rate (7 per cent versus 41 per cent, p = 0.001). Moreover, when the survival result of the 17 newly diagnosed patients were compared with the control, there is a significant improvement in the projected EFS at 3 years (64 per cent versus 25 per cent, p = 0.007). In conclusion, ATRA was shown to improve the CR rate, reduce induction mortality and significantly prolong the event-free survival.
Persistent Identifierhttp://hdl.handle.net/10722/148064
ISSN
2015 Impact Factor: 3.494
2015 SCImago Journal Rankings: 0.767
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChim, CSen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorChu, YCen_HK
dc.contributor.authorChan, CHen_HK
dc.contributor.authorChan, LCen_HK
dc.contributor.authorWong, KFen_HK
dc.contributor.authorChan, TKen_HK
dc.date.accessioned2012-05-29T06:10:39Z-
dc.date.available2012-05-29T06:10:39Z-
dc.date.issued1996en_HK
dc.identifier.citationHematological Oncology, 1996, v. 14 n. 3, p. 147-154en_HK
dc.identifier.issn0278-0232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/148064-
dc.description.abstractAcute promyelocytic leukemia is characterized by the reciprocal translocation of chromosomes 15 and 17. All-trans retinoic acid (ATRA) efficiently induces differentiation of the abnormal promyelocytes. In this study, we had used ATRA as the primary induction therapy for 17 newly diagnosed patients, and as the salvage therapy for 11 patients who relapsed from or were resistant to chemotherapy. All patients received subsequent consolidation chemotherapy. Complete remission (CR) rate, early death rate (within 28 days of diagnosis) were then compared to an historical control of 50 APL patients treated with combination chemotherapy; and event-free survival of the 17 newly diagnosed patients was compared to the historical control. In the ATRA group, 26 of the 28 patients (93 per cent) attained complete remission. Two of 28 (7 per cent) died within 28 days of ATRA therapy. There was no case of primary resistance to ATRA. Combination chemotherapy was added to ATRA in five patients due to rapidly increasing leucocyte count. There was one case of retinoic acid syndrome which resolved with steroid. When compared to the 50 cases of historical control, there is significant improvement in the overall CR rate (92 per cent versus 59 per cent, p = 0.001) and a significant reduction in the early mortality rate (7 per cent versus 41 per cent, p = 0.001). Moreover, when the survival result of the 17 newly diagnosed patients were compared with the control, there is a significant improvement in the projected EFS at 3 years (64 per cent versus 25 per cent, p = 0.007). In conclusion, ATRA was shown to improve the CR rate, reduce induction mortality and significantly prolong the event-free survival.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/3182en_HK
dc.relation.ispartofHematological Oncologyen_HK
dc.rightsHematological Oncology. Copyright © John Wiley & Sons Ltd.-
dc.subjectacute promyelocytic leukemiaen_HK
dc.subjectall-trans retinoic aciden_HK
dc.subjectevent-free survivalen_HK
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Agents - Therapeutic Useen_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshCytarabine - Administration & Dosageen_US
dc.subject.meshDaunorubicin - Administration & Dosageen_US
dc.subject.meshDisease-Free Survivalen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Promyelocytic, Acute - Drug Therapy - Mortalityen_US
dc.subject.meshLife Tablesen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Proteins - Analysisen_US
dc.subject.meshOncogene Proteins, Fusion - Analysisen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRemission Inductionen_US
dc.subject.meshSalvage Therapyen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshTretinoin - Therapeutic Useen_US
dc.titleAll-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL)en_HK
dc.typeArticleen_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.emailChan, LC:chanlc@hkucc.hku.hken_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityChan, LC=rp00373en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/(SICI)1099-1069(199609)14:3<147::AID-HON582>3.0.CO;2-3en_HK
dc.identifier.pmid9119359-
dc.identifier.scopuseid_2-s2.0-0030424531en_HK
dc.identifier.hkuros22795-
dc.identifier.hkuros29865-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030424531&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue3en_HK
dc.identifier.spage147en_HK
dc.identifier.epage154en_HK
dc.identifier.isiWOS:A1996WP56700005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridChu, YC=55209144200en_HK
dc.identifier.scopusauthoridChan, CH=9940314800en_HK
dc.identifier.scopusauthoridChan, LC=7403540707en_HK
dc.identifier.scopusauthoridWong, KF=7404759860en_HK
dc.identifier.scopusauthoridChan, TK=7402687762en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats